TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04443439

Intervention type: DEVICE
Intervention: GE Discovery MR750 3.0t superconducting MRI
Description: T2WI, FLAIR, DWI, 3D BRAVO, 3D-ASL, rs-fMRI, DKI sequences to exclude other organic lesions
Study: NCT02066350

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single pancreas transplantation
Study: NCT01962025

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Buttonhole needling technique
Description: the intervention is the type of needling used for home hemodialysis patients. They will be randomized to either buttonhole cannulation or stepladder cannulation
Study: NCT04961736

Intervention type: OTHER
Intervention: no intervention
Description: This is an observation study, with no intervention

Intervention type: OTHER
Intervention: no intervention
Description: This is an observation study, with no intervention
Study: NCT03729895

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adjustable Oral Appliance
Description: Adjustable Oral Appliance consist of plastic maxillary occlusal splint，mandible occlusal splint and adjustable connecting rod.It could offer a non-invasive form of treatment but also achieve a good therapeutic effect
Study: NCT01468922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Vascular endothelial growth factor (VEGFR) inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ 197
Description: Hepatocyte growth factor receptor (mesenchymal-epithelial transition factor \[c-MET\]) inhibitor
Study: NCT03762928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: single administration of midazolam 2 mg oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: single administration of midazolam 2 mg oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efavirenz
Description: single administration of efavirenz 50 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efavirenz
Description: single administration of efavirenz 50 mg capsule
Study: NCT00598611

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desloratadine
Description: singel dose, oral, 20 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desloratadine
Description: single dose, oral, 5 mg
Study: NCT03839771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-120
Description: 250mg tablets
Study: NCT02054078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab200mg by intrapleural administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pulvis talci
Description: Pulvis talci 4g by intrapleural administration
Study: NCT03147066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dezocine
Description: Dezocine (0.1 mg/kg）will be infused during surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flurbiprofen Axetil
Description: Flurbiprofen Axetil (1 mg/kg）will be infused during surgery
Study: NCT01425164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: ivabradine tablets, 5 to 7.5 mg bis-in-die.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: carvedilol tablets, 12.5 to 25 mg bis-in-die.
Study: NCT01568827

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blackraspberry Slurry
Description: Blackraspberry slurry is 45 g blackraspberry powder mixed in 8oz. water. This is equivalent to 450 g fresh black raspberries.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blackraspberry Slurry
Description: Blackraspberry slurry is 45 g blackraspberry powder mixed in 8oz. water. This is equivalent to 450 g fresh black raspberries.
Study: NCT01887314

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Standardized Ginger extract

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standardized Ginger extract
Study: NCT00649740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate Sprinkle Capsules 25 mg
Description: 25mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topamax® Sprinkle Capsule 25 mg
Description: 25mg, single dose fasting
Study: NCT02264717

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SPECT
Description: Patients are randomized to either SPECT or Cardiac MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac MRI
Description: Patients are randomized to either SPECT or Cardiac MR
Study: NCT01971034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m2, IV, Day 1, Day 8 and Day 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 850mg, PO, every 8 hours, daily.
Study: NCT00895089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (Avelox)
Description: moxifloxacin 400 mg IV qd for 14 days, followed by moxifloxacin 400 mg po qd for another 1 week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftriaxone
Description: ceftriaxone 2 gm IV q 12 h for 14 days, followed by cephalexin 1 gm PO q 6 h for 1 week
Study: NCT01192672

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive Writing
Description: Subjects in the Intervention were instructed to write for 30-minute intervals for 4 consecutive days about their deepest thoughts and feelings related to their Irritable Bowel Syndrome.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Writing
Description: Subjects were asked to write about the actions they performed during the last 24 hours. They were asked not to write about their feelings or thoughts related to these actions.
Study: NCT03363542

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fruits, vegetables and/or whole grain high fiber rich diet
Description: Dietary education to Increase fruits, vegetables and/or high fiber intake

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fruits, vegetables and/or whole grain high fiber rich diet
Description: Dietary education to Increase fruits, vegetables and/or high fiber intake

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fruits, vegetables and/or whole grain high fiber rich diet
Description: Dietary education to Increase fruits, vegetables and/or high fiber intake
Study: NCT01653093

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3-Tesla magnetic resonance imaging (3T MRI)
Description: Undergo 3T MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diffusion-weighted magnetic resonance imaging
Description: Undergo diffusion-weighted MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dynamic contrast-enhanced magnetic resonance imaging
Description: Undergo DCE-MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance spectroscopic imaging
Description: Undergo MR spectroscopy
Study: NCT03709316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZL-2306 (Nirapairb)
Description: The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
Study: NCT02934815

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive-expressive group therapy
Description: The supportive-expressive group therapy (SEGT) is an intervention for women with BC that is designed to build bonds and to facilitate changes in emotional expression and regulation taking into account the role that emotions play in physiologic function, intimately related to the progression of the disease. It is based on seven main themes: building bonds, expressing feelings, detoxifying dying, reordering life priorities, improve support from and communication with family and friends, fortifying families, dealing with doctors, and control pain and anxiety. Although originally developed according to an existential perspective, recently the supportive-expressive group therapy has been used according to an attachment framework.
Study: NCT01258296

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 25 mcg/hr transdermal patch

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inactive patch
Description: placebo patch (no drug)
Study: NCT01589380

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan
Description: Fimasartan, Initial dose will be started with 30mg per day. At 12 months follow-up after the enrollment, dose titration up to 60 mg per day will be made with target blood pressure of 120/80.~Dose escalization from 30mg/day to 60mg/day will be performed in the case of follow-up systolic blood pressure is over 120. If the follow-up systolic blood pressure is less than 120, initial dose of 30mg/day will be maintained throughout the study duration. If hypotension (BP \< 90/60) is developed, the study medication will be discontinued and the patient will be included safety outcome analysis and intention to treat analysis. Per protocol analysis will be also performed. The dose of placebo will be adjusted identically, according to the blood pressure criteria of fimasartan.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was used in phase 3 clinical trial of fimasartan (NCT00922480, NCT01135212, and NCT01258673). The same placebo, which is manufactures at Boryoung pharmaceutical company, will be used in this trial. After enrollment and randomization, placebo will be administered one capsule once daily in placebo group.
Study: NCT03298555

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile phone based intervention
Description: Participants in the intervention group will receive a 6-month mobile phone based program via a mobile phone application specifically designed for this study. The program will include information, advice and strategies to promote healthy gestational weight gain.
Study: NCT01567670

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone
Description: 2 mg x 1-2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: naloxone placebo
Description: h2o placebo spray
Study: NCT04595526

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Forced expiratory technique and induced sputum
Description: The intervention is based on the patient's own attempt to deliver a sputum sample after instructions of proper huff forced exhalation and coughing technique. After an attempt to deliver a sputum sample the patient will receive a 0,9% isotonic saline by an inhalation mask to induce the sputum, thereafter the patient will again make an effort to expectorate a sputum sample repeating the forced expiratory technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal suction
Description: Tracheal suction is often used on intubated patients at the intensive care unit to collect sputum, and this method has become the standard procedure at several emergency departments.
Study: NCT02580214

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Impact
Description: 600 ml of Impact, Nestle for 5 days prior to surgery
Study: NCT01747629

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MDPI
Description: Placebo MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
Study: NCT03839771

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for AG-120
Description: 250mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-221
Description: 100mg tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for AG-221
Description: 100mg tablets
Study: NCT02963558

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cycle ergometry
Description: The cycler will provide 3 different possible modes of cycling-passive, active-assisted, and active. The subject will start with passive cycling and may progress to active-assisted and active cycling.
Study: NCT04246138

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: alignment types
Description: types of alignment mechanical versus kinematic of TKA to be studied

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: alignment types
Description: types of alignment mechanical versus kinematic of TKA to be studied
Study: NCT01747629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol MDPI
Description: Albuterol MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
Study: NCT02811042

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambu AuraOnce
Description: Oropharyngeal leak pressure was determined by closing the expiratory valve of the anaesthesia breathing system and a fixed gas flow of 3 l minute-1. The airway pressure at which an equilibrium was reached was noted (maximum allowed 40 cm H2O).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu AuraGain
Description: The airway tube view was scored using an established scoring system (4=only vocal cords visible; 3=vocal cords plus posterior epiglottis; 2=vocal cords plus anterior epiglottis; 1=vocal cords not seen)
Study: NCT01063127

Intervention type: OTHER
Intervention: Study on insulin sensitivity after diet or bariatric surgery
Description: Group A: 1 week of low calorie diet before gastric banding a new study 1 week after gastric banding Group B: 1 week of low calorie diet before gastric bypass a new study 1 week after gastric bypass

Intervention type: OTHER
Intervention: gastric bypass
Description: Group B: 1 week of low calorie diet before gastric bypass a new study 1 week after gastric bypass
Study: NCT02526771

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional lymph node dissection
Description: conventional lymph node dissection during resection of intrahepatic cholangiocarcinoma

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: unconventional lymph node dissection
Description: unconventional lymph node dissection during resection of intrahepatic cholangiocarcinoma
Study: NCT03081351

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: extended lymphadenectomy and nerve clearance
Description: The investigators will implement the pancreaticoduodenectomy using the principle of Total Peripancreas Excision to resect the lymph node and nerve plexus. The lymph node include standard 5,6,8a,12b1,12b2,12c,12a-b,14a-b,17a-b and extended 8p,9,12a,12p,14a-d,16a2,16b1 of the abdominal lymph node.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard lymphadenectomy
Description: The investigators will implement the pancreaticoduodenectomy using the standard lymphadenectomy. The lymph node include 5,6,8a,12b1,12b2,12c,12a-b,14a-b,17a-b of the abdominal lymph node.
Study: NCT02605772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose
Description: group1:metformin 1.5g + Saxagliptin 5mg group2:acarbose 300mg + Saxagliptin 5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: group1:metformin 1.5g + Saxagliptin 5mg group2:acarbose 300mg + Saxagliptin 5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: group1:metformin 1.5g + Saxagliptin 5mg group2:acarbose 300mg + Saxagliptin 5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: group1:metformin 1.5g + Saxagliptin 5mg group2:acarbose 300mg + Saxagliptin 5mg
Study: NCT02371161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-DHAP/R-ICE
Description: R-DHAP/R-ICE 3 cycles every 21 days:~1. R-DHAP~   * Rituximab 375 mg/m2, e.v. day 1~  * Desamethasone 40 mg days 1-4~  * cis-Platino100 mg/m2, day 2 (if ≥70 years 75 mg/m2)~  * Aracytin 2000 mg/m2, e.v. day 3 (if ≥70 years 1500 mg/m2)~2. R-ICE~   * Rituximab 375 mg/m2, e.v. day 1~  * Etoposide 100 mg/mq, e.v. days 1,2,3 (if ≥70 years 75 mg/mq)~  * Ifosfamide with Mesna equidone 5000 mg/mq, day 2 (if ≥70 years 3750 mg/mq)~  * Carboplatino AUC=5, e.v. (max 800 mg/mq), day 2 (if ≥70 years AUC=4)~Conditioning BEAM or FEAM
Study: NCT04653207

Intervention type: OTHER
Group type: OTHER
Intervention: Glucose Solution 1
Description: 50g glucose dissolve in 300ml of water

Intervention type: OTHER
Group type: OTHER
Intervention: Glucose Solution 2
Description: 50g glucose dissolve in 300ml of water

Intervention type: OTHER
Group type: OTHER
Intervention: Glucose Solution 3
Description: 50g glucose dissolve in 300ml of water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose/Isomaltulose 100:0
Description: 50g sucrose dissolve in 300ml of water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose/Isomaltulose 0:100
Description: 50g isomaltulose dissolve in 300ml of water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose/Isomaltulose 50:50
Description: 25g sucrose and 25g isomaltulose dissolve in 300ml of water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose/Isomaltulose 60:40
Description: 30g sucrose and 20g isomaltulose dissolve in 300ml of water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose/Isomaltulose 70:30
Description: 35g sucrose and 15g isomaltulose dissolve in 300ml of water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose/Isomaltulose 80:20
Description: 40g sucrose and 10g isomaltulose dissolve in 300ml of water
Study: NCT01081730

Intervention type: BIOLOGICAL
Intervention: anti-TNF biologics
Description: as prescribed

Intervention type: OTHER
Intervention: general population
Description: non-treated cohort

Intervention type: BIOLOGICAL
Intervention: non-anti-TNF biologics
Description: as prescribed

Intervention type: BIOLOGICAL
Intervention: ustekinumab
Description: as prescribed

Intervention type: DRUG
Intervention: systemic non-biological treatments
Description: as prescribed
Study: NCT01261455

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Location of the autograft taken following pterygium excision
Description: Following pterygium excision, a conjunctival autograft is taken from either the superior or inferior conjunctiva.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Location of the autograft taken following pterygium excision
Description: Following pterygium excision, a conjunctival autograft is taken from either the superior or inferior conjunctiva.
Study: NCT02958475

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Support Group (Facebook)
Description: The breastfeeding social support group on Facebook will be moderated to facilitate posting of shared experiences. Short videos, photographs, and written blurbs on related topics are posted on the Facebook page to reinforce the messaging and content of the texts.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breastfeeding messages
Description: The Mother's Milk Messaging app gives participants access to text messages via push notification on the app, as well as access to videos and written material to facilitate knowledge acquisition and skills building. The text messages are targeted at specific theoretical constructs such as outcome expectations/attitudes, barrier self-efficacy, reinforcing a message using peripheral (expert) opinion, eliciting a sense of social currency or providing a cue-to-action.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breastfeeding messages
Description: The Mother's Milk Messaging app gives participants access to text messages via push notification on the app, as well as access to videos and written material to facilitate knowledge acquisition and skills building. The text messages are targeted at specific theoretical constructs such as outcome expectations/attitudes, barrier self-efficacy, reinforcing a message using peripheral (expert) opinion, eliciting a sense of social currency or providing a cue-to-action.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Injury Prevention Messages
Description: The Mother's Milk Messaging app will provide participants in the control group with genetic injury prevention message.
Study: NCT03439397

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ballon Technique
Description: Ballon Technique

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SOAI
Description: SOAI
Study: NCT04564859

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heated Humidified High-Flow Nasal Cannula
Description: Participants using of invasive ventilator more than 14 days, maybe considered transferred to the Respiratory Care Center(RCC), participants enrolled to this study and also written informed consent from participants or their family; After extubation, the difficult weaning patients were allocated to two treatment groups, and randomly assigned to Heated Humidified High-Flow Nasal Cannula or Noninvasive Ventilation devices.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heated Humidified High-Flow Nasal Cannula
Description: Participants using of invasive ventilator more than 14 days, maybe considered transferred to the Respiratory Care Center(RCC), participants enrolled to this study and also written informed consent from participants or their family; After extubation, the difficult weaning patients were allocated to two treatment groups, and randomly assigned to Heated Humidified High-Flow Nasal Cannula or Noninvasive Ventilation devices.
Study: NCT04414397

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JUVÉDERM® VOLUMA® XC
Description: JUVÉDERM® VOLUMA® XC injectable gel

Intervention type: DEVICE
Group type: OTHER
Intervention: JUVÉDERM® VOLUMA® XC
Description: JUVÉDERM® VOLUMA® XC injectable gel

Intervention type: OTHER
Group type: OTHER
Intervention: No-treatment control
Description: Participants received no treatment for 3 months during the Control Period.
Study: NCT00130728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: intravenous infusion of bevacizumab at a dose of 15 mg/kg on the first day of each 3-week cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: erlotinib HCl
Description: oral erlotinib HCl 150 mg/day orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: intravenous infusion of placebo at a dose of 15 mg/kg on the first day of each 3-week cycle
Study: NCT01130714

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Resistance training with resistance bands.
Study: NCT00904722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-011
Description: Administered intravenously at a dose of 3.0 mg/kg on days 1, 29 (+/- 7 days), 57 (+/- 7 days), and 85 (+/- 7 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Administered intravenously at the standard dose of 375 mg/m\^2 weekly for 4 weeks on days 17 (+/- 1 day), 24 (+/- 1 day), 31 (+/- 1 day), and 38 (+/- 1 day).